Schering-Plough will work harder on cancer, says Fred Hassan
This article was originally published in Scrip
Executive Summary
Schering-Ploughhas highlighted oncology and Alzheimer's disease as a key part of its future product pipeline. In an interview with Scrip, CEO Fred Hassan identified these areas for their unmet medical need, but bemoaned the high buyout premiums sought by anticancer developers.